Trial Profile

A human bioequivalence study of EPI-002

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EPI-002-Ethicann-Pharmaceuticals (Primary)
Indications Multiple sclerosis
Focus Pharmacokinetics
Sponsors Ethicann Pharmaceuticals

Most Recent Events

06 Feb 2023 New trial record
12 Jan 2023 According to a Catalent media release, Ethicann Pharmaceuticals anticipates performing this study in late 2023-early 2024, in Canada.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com